TCR International Series

Adimab Provides 2022 Update on Clinical Pipeline

Retrieved on: 
Wednesday, January 11, 2023

This brings the total number of Adimab partner programs that have entered the clinic to 62.

Key Points: 
  • This brings the total number of Adimab partner programs that have entered the clinic to 62.
  • Partners have recently filed for BLA approval on three additional programs and another three programs are currently in pivotal trials.
  • “Over the last five years alone, partners have initiated clinical trials for 52 new programs.
  • Bispecifics and T-cell engagers: Adimab has extensive bispecific and multispecific capabilities, including common light chain and fragment-based discovery and engineering.